Board‑Wide Insider Buying Blitz at Talphera Signals Bold Confidence in Growth Path
Insider buying surges at Talphera, signaling board confidence in the company’s pain‑therapy growth and a strong upside potential.
3 minutes to read
TALPHERA INC
CEO of Talphera Inc. Adds 800,000 Shares, Betting on Next Clinical Milestone, Says Investors Should Watch Carefully
CEO’s $0.59 buy of 800k Talphera shares shows bullish outlook amid upcoming nafamostat data—investors gauge short‑term upside and risk.
3 minutes to read
CEO Angotti Buys 213,000 Shares of Talphera Inc. in Mid‑March Surge of Insider Confidence
CEO insider buys 213k Talphera shares at $0.59, signaling short‑term confidence and a potential stabilizing effect on the stock’s price.
3 minutes to read
Nantahala’s Massive Warrant Buy‑Back Signals Talphera Management’s Bold Confidence in Future Upside.
Talphera’s latest insider buying and pre‑funded warrants signal a bullish view on its acute‑pain pipeline, hinting at future upside above $1.00.
2 minutes to read